Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges
暂无分享,去创建一个
[1] Azar Mostoufi,et al. Synthesis, cytotoxicity, apoptosis and molecular docking studies of novel phenylbutyrate derivatives as potential anticancer agents , 2019, Comput. Biol. Chem..
[2] K. Alzoubi,et al. The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells , 2018, Clinical pharmacology : advances and applications.
[3] J. Asadi,et al. Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in breast cancer cell line , 2018 .
[4] A. Nudelman,et al. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors , 2018, Journal of cellular biochemistry.
[5] M. Veldhoen,et al. Microbiota derived short chain fatty acids promote histone crotonylation in the colon through histone deacetylases , 2018, Nature Communications.
[6] L. Morrison,et al. Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid. , 2017, Journal of inorganic biochemistry.
[7] A. Afzal,et al. Short-Chain Fatty Acids Are Antineoplastic Agents , 2017 .
[8] G. Tsourouflis,et al. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer. , 2017, Anticancer research.
[9] G. Drummen,et al. International Journal of Molecular Sciences G Protein-coupled Receptors in Cancer , 2022 .
[10] T. Preston,et al. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism , 2016, Gut microbes.
[11] T. Tomson,et al. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug , 2016, The Lancet Neurology.
[12] R. Franco,et al. Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression , 2015, Oncotarget.
[13] Shiying Yu,et al. Notch signaling: an emerging therapeutic target for cancer treatment. , 2015, Cancer letters.
[14] Christopher Southan,et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors , 2015, British journal of pharmacology.
[15] D. Coy,et al. The Histone Deacetylase Inhibitor Vaproic Acid Induces Cell Growth Arrest in Hepatocellular Carcinoma Cells via Suppressing Notch Signaling , 2015, Journal of Cancer.
[16] Goberdhan P Dimri,et al. MicroRNA-31 Is a Transcriptional Target of Histone Deacetylase Inhibitors and a Regulator of Cellular Senescence* , 2015, The Journal of Biological Chemistry.
[17] Madhusoodanan Mottamal,et al. Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents , 2015, Molecules.
[18] J. Issa,et al. Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia , 2015, Cancer.
[19] Yan-tao Han,et al. Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy , 2015, Medicinal research reviews.
[20] Guoyu Pan,et al. HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review) , 2014, Oncology letters.
[21] S. Brodie,et al. Could valproic acid be an effective anticancer agent? The evidence so far , 2014, Expert review of anticancer therapy.
[22] T. Utsunomiya,et al. Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II. , 2014, Anticancer research.
[23] D. Coy,et al. Anti-Convulsant Drug Valproic Acid in Cancers and in Combination Anti- Cancer Therapeutics , 2014 .
[24] Y. Morine,et al. Effects of valproic acid as a histone deacetylase inhibitor in combination with S-1 on advanced pancreatobiliary tract cancers: Clinical study phases I and II. , 2014 .
[25] Monica Sharma,et al. Histone deacetylase inhibitors: pharmacotherapeutic implications as epigenetic modifier , 2014 .
[26] Bei Liu,et al. Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents in vitro and in vivo , 2013, Oncology letters.
[27] M. Dmoszyńska-Graniczka,et al. [Histone deacetylase inhibitors - molecular mechanisms of actions and clinical applications]. , 2013, Postepy higieny i medycyny doswiadczalnej.
[28] Ø. Bruserud,et al. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents , 2013, Clinical Epigenetics.
[29] S. Artavanis-Tsakonas,et al. Notch signaling at a glance , 2013, Journal of Cell Science.
[30] L. Opitz,et al. Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. , 2013, Carcinogenesis.
[31] J. Fuselier,et al. Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II , 2013, Archives of Gynecology and Obstetrics.
[32] D. Faller,et al. Butyrate Histone Deacetylase Inhibitors , 2012, BioResearch open access.
[33] G. Howarth,et al. Short-Chain Fatty Acids Induce Apoptosis in Colon Cancer Cells Associated with Changes to Intracellular Redox State and Glucose Metabolism , 2012, Chemotherapy.
[34] J. Fuselier,et al. Notch1-mediated tumor suppression in cervical cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted therapeutics. , 2012, The oncologist.
[35] M. Grever,et al. Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer , 2012, Cancer Chemotherapy and Pharmacology.
[36] M. Kobayakawa,et al. Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies , 2011, OncoTargets and therapy.
[37] S. Minucci,et al. Histone deacetylases and epigenetic therapies of hematological malignancies. , 2010, Pharmacological research.
[38] A. Dueñas-González,et al. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. , 2008, Cancer treatment reviews.
[39] E. Werstiuk,et al. Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation. , 2007, European journal of pharmacology.
[40] Michael Rytting,et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.
[41] G. de Murcia,et al. The PARP superfamily , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.